Predictive and prognostic role of tumor-infiltrating lymphocytes for early breast cancer according to disease subtypes: Sensitivity analysis of randomized trials in adjuvant and neoadjuvant setting

Emilio Bria, Giampaolo Tortora, Luisa Carbognin, Sara Pilotto, Rolando Nortilli, Matteo Brunelli, Alessia Nottegar, Isabella Sperduti, Diana Giannarelli

Risultato della ricerca: Contributo in rivistaArticolo in rivista

26 Citazioni (Scopus)

Abstract

Background. The role of tumor-infiltrating lymphocytes (TILs) in breastcancer (BC) is still an issue for clinical research.Toward this end, a sensitivity analysis of neoadjuvant and adjuvant randomized clinical trials was performed according to disease subtypes. Methods. Pathological complete responses (pCRs) after neoadjuvant treatment according to the presence or absence of lymphocyte-predominant BC (LPBC) were extracted and cumulated as odds ratios (ORs) by adopting a random-effects model by subtype. Overall survival hazard ratios as a function of 10% incremental values of stromal TILs (sTILs) in adjuvant trials were extracted. The interaction test was adopted to determine the differential effect according to the subtype. Results. Eight trials (5,514 patients) were identified. With regard to neoadjuvant setting (4 studies), a significant interaction (p < .0001) according to LPBC was found. The presence of LPBC was associated with a 29.5% increase in pCR rate compared with non-LPBC (p < .0001). The pCR rate was significantly higher in patients with LPBC in triple-negative BC (TNBC) and HER2-positive BC settings, with an absolute difference of 15.7% (95% confidence interval [CI], 4.9%–26.2%) and 33.3% (95% CI, 23.6%–42.7%), respectively. With respect to the adjuvant setting (4 studies), a significant interaction (p,.0001) according to sTILs was found. A survival benefit was more likely to be determined for HER2-positive BC (p = .025) and TNBC (p < .0001), with no statistically significant difference for estrogen receptor-positive/HER2- negative disease. Conclusion. Despite the retrospective nature of this analysis, the presence of TILs may represent a robust predictive and prognostic marker for BC, particularly for TNBC and HER2- positive disease.
Lingua originaleEnglish
pagine (da-a)283-291
Numero di pagine9
RivistaTHE ONCOLOGIST
Volume21
DOI
Stato di pubblicazionePubblicato - 2016

Keywords

  • Adjuvant
  • Antineoplastic Combined Chemotherapy Protocols
  • Biomarkers, Tumor
  • Breast cancer
  • Cancer Research
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Female
  • Humans
  • Lymphocytes, Tumor-Infiltrating
  • Neoadjuvant
  • Neoadjuvant Therapy
  • Oncology
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Retrospective Studies
  • Sensitivity analysis
  • Treatment Outcome
  • Triple Negative Breast Neoplasms
  • Tumor-infiltrating lymphocytes

Fingerprint Entra nei temi di ricerca di 'Predictive and prognostic role of tumor-infiltrating lymphocytes for early breast cancer according to disease subtypes: Sensitivity analysis of randomized trials in adjuvant and neoadjuvant setting'. Insieme formano una fingerprint unica.

Cita questo